

## Astepro - (EQ 0.1876/0.125 mg; Base/Spray)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | Azelastine Hydrochloride   | <b>Innovator</b>            | Meda pharma         |
| <b>Dosage</b>                | EQ 0.1876/0.125 mg; Base/Spray   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | Less Than 5  | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | More Than 5  | <b>Generic Launches</b>     | More Than 5         |
| <b>Indication</b>            | Indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.